Physician profile
Florence Arnold
NPI 1225424369
$12,296.04
in general payments reported to CMS, 2019-2025
65 companies · $2,854 in 2025
The $2,854 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,096 · 2020: $1,079 · 2021: $1,047 · 2022: $1,058 · 2023: $1,196 · 2024: $1,967 · 2025: $2,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,982 · Education: $35.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,982.23 |
| Education | $35.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,511.79 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Janssen Biotech, INC. | $1,005.24 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $907.54 | 2019-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $784.74 | 2019-2025 | |
| Pfizer INC. | $507.65 | 2019-2025 | |
| Celgene Corporation | $487.97 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Lilly USA, LLC | $480.22 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $446.79 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Genzyme Corporation | $417.52 | 2019-2025 | |
| Abbvie INC. | $406.33 | 2020-2025 | Venclexta |
| Incyte Corporation | $376.57 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Daiichi Sankyo INC. | $360.24 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Eisai INC. | $348.22 | 2019-2025 | |
| Amgen INC. | $343.78 | 2019-2025 | Imdelltra (Amg757), Kyprolis, Blincyto |
| Regeneron Healthcare Solutions, INC. | $282.69 | 2019-2025 | Libtayo |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florence Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.